333 related articles for article (PubMed ID: 25173780)
21. Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells.
Ramamoorthy JD; Ramamoorthy S; Mahesh VB; Leibach FH; Ganapathy V
Endocrinology; 1995 Mar; 136(3):924-32. PubMed ID: 7867601
[TBL] [Abstract][Full Text] [Related]
22. New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents.
Chu W; Xu J; Zhou D; Zhang F; Jones LA; Wheeler KT; Mach RH
Bioorg Med Chem; 2009 Feb; 17(3):1222-31. PubMed ID: 19119012
[TBL] [Abstract][Full Text] [Related]
23. Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines.
Alamri MA; Ates-Alagoz Z; Adejare A
Med Chem; 2020; 16(2):192-201. PubMed ID: 30827254
[TBL] [Abstract][Full Text] [Related]
24. Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1.
Pati ML; Groza D; Riganti C; Kopecka J; Niso M; Berardi F; Hager S; Heffeter P; Hirai M; Tsugawa H; Kabe Y; Suematsu M; Abate C
Pharmacol Res; 2017 Mar; 117():67-74. PubMed ID: 28007569
[TBL] [Abstract][Full Text] [Related]
25. N-[18F]4'-fluorobenzylpiperidin-4yl-(2-fluorophenyl) acetamide ([18F]FBFPA): a potential fluorine-18 labeled PET radiotracer for imaging sigma-1 receptors in the CNS.
Mach RH; Gage HD; Buchheimer N; Huang Y; Kuhner R; Wu L; Morton TE; Ehrenkaufer RL
Synapse; 2005 Dec; 58(4):267-74. PubMed ID: 16206186
[TBL] [Abstract][Full Text] [Related]
26. Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers.
Abate C; Ferorelli S; Contino M; Marottoli R; Colabufo NA; Perrone R; Berardi F
Eur J Med Chem; 2011 Sep; 46(9):4733-41. PubMed ID: 21684636
[TBL] [Abstract][Full Text] [Related]
27. Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy.
Megalizzi V; Le Mercier M; Decaestecker C
Med Res Rev; 2012 Mar; 32(2):410-27. PubMed ID: 20687157
[TBL] [Abstract][Full Text] [Related]
28. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo.
Mach RH; Wheeler KT
Cent Nerv Syst Agents Med Chem; 2009 Sep; 9(3):230-45. PubMed ID: 20021357
[TBL] [Abstract][Full Text] [Related]
29. In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
Rybczynska AA; de Bruyn M; Ramakrishnan NK; de Jong JR; Elsinga PH; Helfrich W; Dierckx RA; van Waarde A
J Nucl Med; 2013 Sep; 54(9):1613-20. PubMed ID: 23940303
[TBL] [Abstract][Full Text] [Related]
30. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.
Fontanilla D; Johannessen M; Hajipour AR; Cozzi NV; Jackson MB; Ruoho AE
Science; 2009 Feb; 323(5916):934-7. PubMed ID: 19213917
[TBL] [Abstract][Full Text] [Related]
31. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation.
van Waarde A; Jager PL; Ishiwata K; Dierckx RA; Elsinga PH
J Nucl Med; 2006 Jan; 47(1):150-4. PubMed ID: 16391199
[TBL] [Abstract][Full Text] [Related]
32. Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumour cells and tumour-bearing rats.
Rybczynska AA; Elsinga PH; Sijbesma JW; Ishiwata K; de Jong JR; de Vries EF; Dierckx RA; van Waarde A
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1167-75. PubMed ID: 19247652
[TBL] [Abstract][Full Text] [Related]
33. Current development of sigma-2 receptor radioligands as potential tumor imaging agents.
Shaghaghi Z; Alvandi M; Ghanbarimasir Z; Farzipour S; Emami S
Bioorg Chem; 2021 Oct; 115():105163. PubMed ID: 34289426
[TBL] [Abstract][Full Text] [Related]
34. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells.
van Waarde A; Been LB; Ishiwata K; Dierckx RA; Elsinga PH
J Nucl Med; 2006 Sep; 47(9):1538-45. PubMed ID: 16954564
[TBL] [Abstract][Full Text] [Related]
35. Ion channel expression as promising cancer biomarker.
Lastraioli E; Iorio J; Arcangeli A
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2685-702. PubMed ID: 25542783
[TBL] [Abstract][Full Text] [Related]
36. Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands.
Sahn JJ; Hodges TR; Chan JZ; Martin SF
ChemMedChem; 2016 Mar; 11(6):556-61. PubMed ID: 26915462
[TBL] [Abstract][Full Text] [Related]
37. Development and evaluation of a radiobromine-labeled sigma ligand for tumor imaging.
Ogawa K; Kanbara H; Kiyono Y; Kitamura Y; Kiwada T; Kozaka T; Kitamura M; Mori T; Shiba K; Odani A
Nucl Med Biol; 2013 May; 40(4):445-50. PubMed ID: 23528561
[TBL] [Abstract][Full Text] [Related]
38. Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels.
Johannessen M; Fontanilla D; Mavlyutov T; Ruoho AE; Jackson MB
Am J Physiol Cell Physiol; 2011 Feb; 300(2):C328-37. PubMed ID: 21084640
[TBL] [Abstract][Full Text] [Related]
39. Early development of sigma-receptor ligands.
Narayanan S; Bhat R; Mesangeau C; Poupaert JH; McCurdy CR
Future Med Chem; 2011 Jan; 3(1):79-94. PubMed ID: 21428827
[TBL] [Abstract][Full Text] [Related]
40. Sigma receptors and cancer: possible involvement of ion channels.
Aydar E; Palmer CP; Djamgoz MB
Cancer Res; 2004 Aug; 64(15):5029-35. PubMed ID: 15289298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
